An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Metsera Inc.’s shares jumped after the obesity startup shared better-than-expected data on a weight-loss shot that would ...

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

Metsera (NASDAQ:MTSR) added ~16% on Tuesday as Wall Street continued to cheer early-stage trial data the company posted for ...

Metsera has linked its amylin analog to 8.4% placebo-adjusted weight loss at Day 36, advancing its push to develop an ...

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...

Metsera, the obesity-focused biotech, said this morning that its drug candidate targeting the amylin hormone showed marked ...

Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial, the company said ...